Search research articles
Contact Us
Filters
Showing results (1-10 of 86) with videos related to
Page
of 9
Sort By:
Therapeutic Advances in Medical Oncology
|
October 7, 2021
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer
Robert Hettle, Charles McCrea, Chee Khoon Lee, et al.
World Journal of Surgical Oncology
|
January 23, 2009
When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis
Chee Khoon Lee, Alison Hadley, Keshani Desilva, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 20, 2018
Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis
Johnathan Man, Georgia Ritchie, Matthew Links, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2018
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial
Chee Khoon Lee, Silvia Novello, Anna Rydén, et al.
BMJ Open
|
July 12, 2022
Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance
Doah Cho, Saskia Cheyne, Sarah J Lord, et al.
Health and Quality of Life Outcomes
|
January 14, 2018
When do patient reported quality of life indicators become prognostic in breast cancer?
Chee Khoon Lee, Malcolm Hudson, John Simes, et al.
JCO Precision Oncology
|
July 23, 2021
Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis
Peey-Sei Kok, Won-Hee Yoon, Sally Lord, et al.
JAMA Oncology
|
February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis
Georgia Ritchie, Harry Gasper, Johnathan Man, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2021
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Katherine E Francis, Val Gebski, Sarah J Lord, et al.
Therapeutic Advances in Medical Oncology
|
August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for <i>HER2</i>-amplified tumors off-label? Illustrating an extrapolation framework
Doah Cho, Sarah J Lord, John Simes, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 86) with videos related to
Sort By:
Page
of 9
Therapeutic Advances in Medical Oncology
|
October 7, 2021
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab <i>versus</i> bevacizumab alone in women with newly diagnosed advanced ovarian cancer
Robert Hettle, Charles McCrea, Chee Khoon Lee, et al.
World Journal of Surgical Oncology
|
January 23, 2009
When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis
Chee Khoon Lee, Alison Hadley, Keshani Desilva, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 20, 2018
Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis
Johnathan Man, Georgia Ritchie, Matthew Links, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 8, 2018
Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial
Chee Khoon Lee, Silvia Novello, Anna Rydén, et al.
BMJ Open
|
July 12, 2022
Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance
Doah Cho, Saskia Cheyne, Sarah J Lord, et al.
Health and Quality of Life Outcomes
|
January 14, 2018
When do patient reported quality of life indicators become prognostic in breast cancer?
Chee Khoon Lee, Malcolm Hudson, John Simes, et al.
JCO Precision Oncology
|
July 23, 2021
Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis
Peey-Sei Kok, Won-Hee Yoon, Sally Lord, et al.
JAMA Oncology
|
February 23, 2018
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis
Georgia Ritchie, Harry Gasper, Johnathan Man, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2021
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Katherine E Francis, Val Gebski, Sarah J Lord, et al.
Therapeutic Advances in Medical Oncology
|
August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for <i>HER2</i>-amplified tumors off-label? Illustrating an extrapolation framework
Doah Cho, Sarah J Lord, John Simes, et al.
Page
of 9